What can you try before shoulder surgery?

What helps at home first?

Break heavy jobs into smaller parts and hold loads close. A therapist can show movements for your present motion and strength. The work shouldn't leave your shoulder much worse the next day. Medicine may help, but your doctor must consider your heart, kidneys and stomach.

Practice comfortable movements often. Repeatedly testing the painful reach can stir up the soreness.

What does QC Kinetix discuss at a visit?

QC Kinetix offers regenerative treatments, or nonsurgical care made with your blood and given at the clinic. One choice is concentrated platelet-rich plasma, a blood portion that a machine separates so it holds more platelets. It's offered to ease soreness and improve daily use.

A clinician won't offer this care before examining your shoulder and reviewing your health. Ask whether improvement for you would mean better sleep, easier dressing or a higher reach. If it isn't right for your shoulder, the clinician may suggest other care.

When does surgery enter the discussion?

Lasting soreness, stiffness and lost use can lead to a surgery talk. A sudden tendon tear after an injury may need an earlier visit with a surgeon. Shoulder replacement is for severe joint wear, not every sore shoulder. A surgeon considers the joint, tendons, bone and your general health.

You can still decline surgery after that visit. The surgeon's reasons can help you choose between waiting and moving ahead.

Sources

1. The GRASP trial randomized 708 adults with a rotator cuff disorder to progressive exercise (up to 6 sessions), a single best-practice advice session, or either of those preceded by a corticosteroid injection. Over 12 months there was no evidence of a difference in Shoulder Pain and Disability Index between progressive exercise and one advice session (adjusted mean difference -0.66, 99% CI -4.52 to 3.20), and no evidence of a difference between having a corticosteroid injection and not having one.

   Hopewell S, et al. — Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.. Lancet, 2021. DOI: 10.1016/S0140-6736(21)00846-1.

2. A double-blind randomized trial of 70 patients with chronic glenohumeral osteoarthritis compared a single ultrasound-guided leukocyte-poor PRP injection with hyaluronic acid. There were NO significant between-group differences in SPADI, ASES or pain at any point to 12 months; both groups improved significantly from 1-2 months onward regardless of arthritis severity, and platelet yield had no effect on outcome in the PRP arm.

   Kirschner JS, et al. — Efficacy of Ultrasound-Guided Glenohumeral Joint Injections of Leukocyte-Poor Platelet-Rich Plasma Versus Hyaluronic Acid in the Treatment of Glenohumeral Osteoarthritis: A Randomized, Double-Blind Controlled Trial.. Clin J Sport Med, 2022. DOI: 10.1097/JSM.0000000000001029.

3. A systematic review and meta-analysis of hyaluronic acid for glenohumeral osteoarthritis found VAS pain reductions of 26.2 mm at 3 months and 29.5 mm at 6 months - but SIMILAR clinical improvements in the control groups, which the authors read as evidence of a substantial placebo effect from intra-articular shoulder injection itself.

   Zhang B, et al. — Outcomes of hyaluronic acid injections for glenohumeral osteoarthritis: a systematic review and meta-analysis.. J Shoulder Elbow Surg, 2019. DOI: 10.1016/j.jse.2018.09.011.

4. A meta-analysis of 15 randomized trials (1,023 subjects) found intra-articular hyaluronic acid combined with physical therapy outperformed physical therapy alone (effect size 4.43, p=0.00006) and improved VAS pain compared with corticosteroid injection (p=0.002) in glenohumeral osteoarthritis - with the caveat that 46.7% of included studies showed probable signs of randomization bias.

   Familiari F, et al. — Efficacy of intra-articular injections of hyaluronic acid in patients with glenohumeral joint osteoarthritis: A systematic review and meta-analysis.. J Orthop Res, 2023. DOI: 10.1002/jor.25648.

5. A 2025 systematic review of 1,125 patients receiving intra-articular injections for glenohumeral osteoarthritis reported a 7.2% overall complication rate and a 3.2% rate of proceeding to surgery. Hyaluronic acid showed consistent though modest benefit, while the evidence for ORTHOBIOLOGICS (PRP, bone marrow aspirate concentrate, mesenchymal stem cells) 'remains limited', mainly because of heterogeneity in design, outcomes and patient characteristics.

   Migliorini F, et al. — Intra-articular injections for shoulder arthritis in adults: a systematic review.. Eur J Med Res, 2025. DOI: 10.1186/s40001-025-03423-4.

6. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

7. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

8. UK FROST randomized 503 adults with primary frozen shoulder to manipulation under anaesthesia, arthroscopic capsular release, or early structured physiotherapy with steroid injection. At 12 months every between-group difference on the Oxford Shoulder Score was smaller than the target difference, so NONE of the three was clinically superior. Capsular release carried the most serious adverse events (8 versus 2 with manipulation), and manipulation under anaesthesia was the most cost-effective.

   Rangan A, et al. — Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial.. Lancet, 2020. DOI: 10.1016/S0140-6736(20)31965-6.

9. At 10 years, arthroscopic subacromial decompression offered NO benefit over placebo surgery for subacromial pain syndrome: the mean difference in VAS pain was -1.5 points (95% CI -8.6 to 5.6) at rest and -3.2 points (-13.0 to 6.5) on arm activity, against a minimally important difference of 15. It also showed no benefit over exercise therapy.

   Kanto K, et al. — Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trial.. BMJ, 2025. DOI: 10.1136/bmj-2025-086201.